Email this article 
Possibilities of reparative therapy in the treatment of patients with xerotic changes in the cornea
- Authors: Brzheskiy V.V.1, Bobryshev V.A.1
-
Affiliations:
- Saint Petersburg State Pediatric Medical University
- Issue: Vol 17, No 1 (2024)
- Pages: 63-70
- Section: Problems of ophthalmic pharmacology
- Submitted: 15.01.2024
- Accepted: 03.02.2024
- Published: 09.03.2024
- URL: https://journals.eco-vector.com/ov/article/view/625682
- DOI: https://doi.org/10.17816/OV625682
- ID: 625682
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
In recent years, in the treatment of patients with dry eye syndrome, drugs that, along with moisturizing, also have specific metabolic properties, due to the additional medicinal ingredients contained in them, deserve more and more attention. The article presents comparative data on the preparations of “artificial tears” and so-called keratoprotectors registered in Russia. In addition, a number of experimental and clinical studies by domestic authors evaluating the pharmacological and clinical effect of the new keratoprotector SPHERO®oko were reviewed. Much attention is also paid to the consideration of the original direction of SPHERO®oko application — its introduction into the corneal stroma (together with a dye) for cosmetic and functional keratopigmentation in the presence of extensive iris defects. The authors of the literature review, taking into account the results of numerous experimental studies and some clinical observations, believe that the use of SPHERO®oko has quite great opportunities in the complex treatment of xerotic changes of the cornea and conjunctiva. At the same time, it is of interest to continue the research on the possibilities of intrastromal administration of colored SPHERO®oko for keratopigmentation in the presence of extensive iris defects.
Full Text
In recent years, the treatment of dry eye syndrome has moved beyond the use of artificial tears for hydrating the ocular surface to include reparative therapy for xerophthalmic changes [1].
However, the boundary between tear replacement and reparative therapy is blurred. Ocular surface hydration alone helps to improve metabolic processes in xerophthalmic cornea and conjunctiva [2]. This potentially promotes conjunctival gland secretion of mucins and the aqueous component of the tear film and glycocalyx formation of corneal and conjunctival epithelial cells [1, 2]. In addition, artificial tear therapy helps to reduce the osmolarity of the tear film, thus preventing and alleviating hyperosmolar stress and reducing the severity of inflammation in the ocular surface tissues. This, in turn, promotes reparative processes [1, 2].
Moreover, many polymeric bases of artificial tears also have reparative properties (natural mucopolysaccharides such as high molecular weight hyaluronic acid, hydroxypropyl guar, chondroitin sulfate, some synthetic polymers such as polyvinyl alcohol, etc.) [1, 3–8].
Meanwhile, there is also a growing interest in pharmaceutical products (ophthalmic solutions, gels, and ointments) that, in addition to their moisturizing properties, have specific metabolic properties due to additional active ingredients [1–4]. According to the Anatomical Therapeutic Chemical Classification (ATC), most of them are classified as corneal moisturizers and corneal protectors. However, with regard to the above-mentioned conditions, the boundaries between them and “classic” artificial tears are vague (see figure)*.
Figure. The mechanism of achieving a metabolic effect of some artificial tears and keratoprotectors
Рисунок. Механизм достижения метаболического эффекта некоторых препаратов «искусственной слезы» и кератопротекторов
*rlsnet.ru/atc [online]. Russia State Registry of Medicines® [Accessed on January 14, 2024]. Available at: https://www.rlsnet.ru/atc; rlsnet.ru/ [online]. Russia State Registry of Medicines® [Accessed on January 14, 2024]. Available at: https://www.rlsnet.ru/taa/groups/medicinskie-izdeliya-sredstva-uxoda-i-gigieny-10
It seems more logical to evaluate all these compounds based on their pharmacological properties rather than the said conventional ATC classification. The situation is further complicated by the categorization of products as either drugs or medical products. Most of such formulations fall into the latter category. With these caveats in mind, we consider the potential of reparative therapies for the xerophthalmic changes that have emerged in recent years.
The table lists artificial tears and corneal protectors that have proven metabolic properties in addition to moisturizing properties.
In 2015, the range of such agents was expanded with the Russian approval of SPHERO®oko (BIOMIR Servis JSC, Russia), a multicomponent hydrogel biomimetic of the extracellular matrix [9].
SPHERO®oko is a biopolymer gel derived from the hydrolysate of embryonic or postnatal animal collagen tissues with minimal immunogenicity. The product contains both major components of the extracellular matrix (collagen, proteoglycans, and glycoproteins) and other biologically active substances, including peptides, amino acids, uronic acids, monosaccharides, growth factors, etc.
The multi-component nature of SPHERO®oko increases the metabolic activity of the epithelial cells of the ocular surface, promotes their proliferation and differentiation, and ultimately accelerates the reparative regeneration of the xerotic tissues of the cornea and conjunctiva. In addition, SPHERO®oko has anti-inflammatory, anti-congestant, and tear-substitution activities, and prevents corneal neovascularization, etc. [10].
SPHERO®oko is indicated for use in recurrent corneal erosion, filamentary keratitis, toxic corneal erosion, keratoconjunctivitis sicca, as well as for wearing orthokeratological contact lenses (the gel is administered under the orthokeratological contact lenses).
Numerous Russian experimental and clinical studies have demonstrated the pharmacological and clinical effects of SPHERO®oko and evaluated its tolerability in patients.
Table. “Artificial tears” and so-called keratoprotectors with reparative properties, registered in Russia
Таблица. Зарегистрированные в России препараты «искусственной слезы» и кератопротекторы, обладающие репаративными свойствами
Active substance | Trade name | Manufacturer |
Dexpanthenol 5% | Corneregel* | Bausch+Lomb |
Dexpantel* | Tatchempharmpreparaty JSC | |
Dexpanthenol 2% | Systane® Ultra Plus | Alcon |
Hylozar-Comod®* | Ursapharm | |
Hypromeloza-P* | Unimedpharma | |
Optinol® Soft recovery | Jadran | |
Dexpanthenol 1% | Stillavit® | Stada |
Sodium hyaluronate (0.1%–0.4%) | Artelac® Splash, Artelac® Splash Uno, Artelac® Balance, Artelac® Balance Uno, Artelak® Night, Oxyal | Bausch+Lomb |
Hylo-Comod®, Hylozar-Comod®, Hyloparin-Comod® | Ursapharm | |
Hylabak | Thea | |
Vismed, Vismed light, Vismed multi, Vismed gel | TRB Chemedica | |
Ocutears® Hydro+ | Santen | |
Gylan Comfort, Gylan Ultra Comfort | Solopharm | |
Systane® Ultra Plus | Alcon | |
Eyestill | Sifi, NovaMedica | |
Optinol®: Express Moisture (0.21%) and Deep Moisture (0.4%) | Jadran | |
Chondroitin sulfate | Stillavit® | Stada, Oftalm-Renessans |
Ocvis | Dubna-Biofarm LLC | |
Hydroxypropyl guar | Systane® Ultra, Systane® Ultra (monodoses), Systane® Ultra Plus, Systane® Balance, Systane® Gel | Alcon |
TS-polysaccharide | Visine® True Tears, Visine® True Tears (1 day) | Johnson & Johnson |
Vitamin A palmitate | VitA-POS® | Ursapharm |
Heparin | Parin-Pos®, Hyloparin-Comod | Ursapharm |
Deproteinized hemodialysate | Solcoseryl®* (state marketing authorization expired in 2022) | Legacy Pharmaceuticals Switzerland |
Glycoprotein 0.01% | Adgelon®* | Endo-Pharm-A CJSC |
Glycosaminoglycans, sulfated 0.01% | Balarpan®* | Scientific Experimental and Production Base “MNTK “Eye Microsurgery” |
Collagen-containing extract (of animal origin) | SPHERO®oko | BIOMIR Servis JSC |
*Regenerants and reparants and/or corneal protectors.
In 2017, I.A. Pronkin demonstrated the pharmacological effect of the study corneal protector in a rabbit model of grade III alkali corneal burn [11]. The combined use of the corneal epithelial protector SPHERO®oko resulted in a more structured and anatomically correct healing of the cornea compared to other metabolic products.
In addition, further clinical observations demonstrated the efficacy of the study formulation (in combination with 5% dexpanthenol) in patients with recurrent corneal erosion and filamentary keratitis. Addition of SPHERO®oko to the treatment regimen accelerated corneal epithelialization by an average of 41.5% in patients with recurrent corneal erosion and provided epithelial filament resorption in patients with filamentary keratitis. In addition, the potential of using the study corneal protector with a bandage soft contact lens was investigated [11].
Besides, initial positive results with SPHERO®oko were obtained in corneal erosions of various origins, when used as a component of local metabolic combination therapy after keratorefractive surgery (radial keratotomy) [12] and as reparative monotherapy after metaherpetic keratitis [10]. During 2 weeks of treatment in the first case and 1 month of treatment in the second case, complete corneal epithelialization and resolution of clinical symptoms of corneal erosion were achieved [10, 12].
We also introduced SPHERO®oko into our clinical practice in 2021. Our studies evaluated the potential of its use in the combination therapy in children and adults with stage 2 neurotrophic keratopathy (Mackie classification [13]) associated with extensive persistent corneal erosion (4 patients, 6 eyes) [14].
To summarize, after four applications in the conjunctival sac over 3 weeks, SPHERO®oko showed a tendency towards corneal epithelialization in all cases, and the originally planned corneal amnioplasty was cancelled. Moreover, all patients tolerated the conservative therapy well.
One of the original issues of SPHERO®oko is injection into the corneal stroma (using inorganic toner as dye) for cosmetic purposes and functional corneal pigmentation of extensive iris defects [15]. Using human corneal cultures, S.B. Izmailova et al. [15] demonstrated that an intracorneal colored gel implant based on SPHERO®oko was best suited for these purposes. Its structure was more compact and more dense compared to similar experimental products (based on sodium hyaluronate and hydroxypropyl methylcellulose) and met the requirements. The authors plan to continue these in vivo animal studies [15].
Based on extensive experimental data and clinical observations, SPHERO®oko has great potential for use in the combination treatment of corneal and conjunctival xerophthalmic changes. It is expedient to further explore the potential of intrastromal injection of colored SPHERO®oko for cosmetic and functional purposes.
ADDITIONAL INFORMATION
Authors’ contribution. Thereby, all authors made a substantial contribution to the conception of the study, acquisition, analysis, interpretation of data for the work, drafting and revising the article, final approval of the version to be published, and agree to be accountable for all aspects of the study.
Personal contribution of each author: V.V. Brzeskii — concept and design of the study, editing; V.V. Brzeskii, V.A. Bobryshev — collection and processing of material, writing the text.
Funding source. This study was not supported by any external sources of funding.
Competing interests. The authors declare that they have no competing interests.
About the authors
Vladimir V. Brzheskiy
Saint Petersburg State Pediatric Medical University
Author for correspondence.
Email: vvbrzh@yandex.ru
ORCID iD: 0000-0001-7361-0270
http://www.eye-gpma.ru/?p=brzheskij65
MD, Dr. Sci. (Medicine), Professor
Russian Federation, 2 Litovskaya st., Saint Petersburg, 194100Vsevolod A. Bobryshev
Saint Petersburg State Pediatric Medical University
Email: vvbrzh@yandex.ru
ORCID iD: 0000-0002-3999-7173
Russian Federation, 2 Litovskaya st., Saint Petersburg, 194100
References
- Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and therapy report. Ocul Surf. 2017;15(3):575–628. doi: 10.1016/j.jtos.2017.05.006
- Brzheskiy VV, Egorova GB, Egorov EA. Dry eye syndrome and ocular surface diseases: clinic, diagnosis, treatment. Moscow: GEOTAR-Media, 2016. 464 p. (In Russ.)
- Brzheskiy VV. Combined artificial tear medications in the treatment of patients with dry eye syndrome. Russian Ophthalmological Journal. 2022;15(2):154–159. EDN: EQERUJ doi: 10.21516/2072-0076-2022-15-2-154-159
- Williams D. Improving ophthalmic tear replacement therapies: A bioengeneering approach: mini review. Curr Trends Biomed Eng Biosci. 2017;2(3):555589. doi: 10.17863/CAM.11344
- Brzheskiy VV, Popov VYu, Kalinina NM, Brzheskaya IV. Prevention and treatment of degenerative changes in ocular surface epithelium in patients with dry eye syndrome. The Russian annals of ophthalmology. 2018;134(5):126–134. EDN: YNPYDR doi: 10.17116/oftalma2018134051126
- Fallacara A, Baldini E, Manfredini S, Vertuani S. Hyaluronic acid in the third millennium: Review. Polymers. 2018;10(7):701. doi: 10.3390/polym10070701
- Fallacara A, Manfredini S, Durini E, Vertuani S. Hyaluronic acid fillers in soft tissue regeneration. Facial Plast Surg. 2017;33(1):87–96. doi: 10.1055/s-0036-1597685
- Krishna N, Brown F. Polyvinyl alcohol as an ophthalmic vehicle: Effect on regeneration of corneal epithelium. Amer J Ophthalmol. 1964;55(2):99–106. doi: 10.1016/0002-9394(64)92038-0
- Sevastianov V, Perova N. Part I. Extracellular matrix biomimetics. Chapter One. Multicomponent hydrogel biomimetics of extracellular matrix. In: Sevastianov VI, Basok YB, eds. Biomimetics of extracellular matrices for cell and tissue engineered medical products. United Kingdom: Cambridge Scholars Publishing, 2023.
- Maychuk DYu, Tarkhanova AA, Pronkin IA. Ophthalmic products with extracellular matrix components. Their effectiveness in the process of corneal repair in neurotrophic, herpetic, recurrent keratitis and erosions. Fyodorov journal of ophthalmic surgery. 2022;(2):91–100. EDN: UTJFNG doi: 10.25276/0235-4160-2022-2-91-100
- Pronkin IA. Method of therapy of recurrent corneal epithelial defects based on 1.5 % collagen-containing gel corneal epithelial protector [dissertation abstract]. Moscow, 2017. 24 p. (In Russ.)
- Semakina AS. Experience of using corneal epithelium protector gel for the treatment of corneal erosion for a patient after radial keratotomy. Ophthalmology in Russia. 2022;19(2):441–443. EDN: NYHFGX doi: 10.18008/1816-5095-2022-2-441-443
- Mackie IA. Chapter 205: Neuroparalytic keratitis 370.35 (Neurotrophic keratitis, Trigeminal neuropathic keratopathy). In: Roy FH, Frederick WF, Frederick TF, editors. Roy and Fraunfelder’s current ocular therapy. 6th edit. Philadelphia, 1995. P. 452–454. doi: 10.1016/B978-1-4160-2447-7.50210-3
- Brzheskiy VV, Popov VYu, Efimova EL, Golubev SYu. Modern capabilities in diagnosis and treatment of neurotrophic keratopathy. The Russian annals of ophthalmology. 2022;138(6):123–132. EDN: CWJCNB doi: 10.17116/oftalma2022138061111
- Izmailova SB, Borzenok SA, Komarova OYu, Ostrovkiy DS. Research of the developed gel intracorneal colored implants for keratopigmentation based on various materials. Experimental study. Fyodorov journal of ophthalmic surgery. 2021;(2):40–47. EDN: URVKVV doi: 10.25276/0235-4160-2021-2-40-47
Supplementary files
